Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: Stock Traders Daily
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actavis plc completes acquisition of Furiex Pharmaceuticals Inc

Wednesday, 2 Jul 2014 08:46am EDT 

Actavis plc:Completes acquisition of Furiex Pharmaceuticals, Inc. in all-cash transaction valued at about $1.1 bln, and up to about $360 mln in Contingent Value Right that may be payable based on status of eluxadoline, Furiex's lead product, as controlled drug following approval.Says in connection with close of Furiex acquisition, Actavis further announced that it has closed the transaction related to the sale of Furiex's royalties on alogliptin and Priligy to Royalty Pharma for about $415 mln. 

Company Quote

4.38 +1.71%
17 Dec 2014